Latest Conference Articles

June 2nd 2015, 5:35am

ASCO Annual Meeting

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).

June 1st 2015, 4:26pm

ASCO Annual Meeting

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the phase III SQUIRE study.

June 1st 2015, 1:48pm

ASCO Annual Meeting

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer types aims to test the efficacy of more than 20 drugs simultaneously in an ambitious National Cancer Institute plan to further propel oncology drug discovery into the precision medicine era.

June 1st 2015, 11:06am

ASCO Annual Meeting

At the 2015 ASCO Annual Meeting, the much heralded CancerLinQ big data system for helping oncologists more clearly understand treatment patterns and options was offered for demonstration in advance of its rollout.

June 1st 2015, 10:39am

ASCO Annual Meeting

Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.

June 1st 2015, 5:25am

ASCO Annual Meeting

Ben Creelan, MD, medical oncologist with Moffitt Cancer Center, discusses the results from a phase I study of MEDI4736, an anti-PD-L1 antibody in combination with gefitinib, an EGFR inhibitor, in patients with non-small-cell lung cancer (NSCLC).

May 31st 2015, 4:48pm

ASCO Annual Meeting

In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.

May 31st 2015, 4:14pm

ASCO Annual Meeting

Treatment with eribulin (Halaven) improved overall survival by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma and adipocytic sarcoma.

May 31st 2015, 3:46pm

ASCO Annual Meeting

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.

May 31st 2015, 2:34pm

ASCO Annual Meeting

Elective neck dissection performed at the same time patients have surgery for early-stage, node-negative, oral squamous cell cancer significantly improved overall survival and reduced the risk of death and recurrence when compared with a watchful waiting approach.

May 31st 2015, 2:30pm

ASCO Annual Meeting

Patients with small brain metastases from other tumor types should not routinely receive adjuvant whole brain radiation therapy (WBRT), according to a study that showed the treatment dramatically increases the incidence of cognitive decline without improving survival outcomes.

May 31st 2015, 2:26pm

ASCO Annual Meeting

Novel targeted therapies against ALK, BRAF, and RET have demonstrated promising outcomes in molecularly-defined patients with non-small cell lung cancer.

May 31st 2015, 1:48pm

ASCO Annual Meeting

Frontline nivolumab as monotherapy and in combination with ipilimumab more than doubled progression-free survival versus ipilimumab alone in patients with advanced melanoma.

May 31st 2015, 10:31am

ASCO Annual Meeting

Patients with melanoma who are found to have micrometastases after an initial positive sentinel node biopsy can safely forgo a complete lymph node dissection, thus avoiding the risk of debilitating adverse events from the surgery.

May 31st 2015, 8:52am

ASCO Annual Meeting

Treatment with atezolizumab doubled overall survival compared with docetaxel in previously treated patients with PD-L1-positive squamous and non-squamous non-small cell lung cancer.

May 31st 2015, 8:46am

ASCO Annual Meeting

An immunotherapy combination demonstrated "high levels of clinical activity" in previously treated non-small cell lung cancer across a range of doses.

May 31st 2015, 5:17am

ASCO Annual Meeting

The first study to compare the efficacy and safety of tamoxifen versus anastrozole in women treated for ductal carcinoma in situ suggests that anastrozole may be the better choice for preventing the escalation of DCIS into invasive cancer.

May 31st 2015, 5:07am

ASCO Annual Meeting

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses the results of a phase III randomized, controlled study evaluating idelalisib (Zydelig) in combination with ofatumumab (Arzerra) compared to ofatumumab alone for previously treated CLL.

May 31st 2015, 5:00am

ASCO Annual Meeting

Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

May 30th 2015, 3:35pm

ASCO Annual Meeting

Patients with relapsed indolent non-Hodgkin lymphoma experienced a doubling of progression-free survival when treated with a combination of the anti-CD20 agent obinutuzumab and bendamustine.